Inleiding richtlijn de ziekte van Parkinson - Medisch Contact

(181) Clarke CE, Deane KH. Cabergoline for levodopa-induced complications in Parkinson's
disease. Cochrane Database Syst Rev 2001;(1):CD001518.
(182) Clarke CE, Deane KH. Ropinirole for levodopa-induced complications in Parkinson's
disease. Cochrane Database Syst Rev 2001;(1):CD001516.
(183) van Hilten JJ, Ramaker C, Van de Beek WJ, Finken MJ. Bromocriptine for levodopainduced
motor complications in Parkinson's disease. Cochrane Database Syst Rev
2000;(2):CD001203.
(184) Mizuno Y, Yanagisawa N, Kuno S, Yamamoto M, Hasegawa K, Origasa H et al.
Randomized, double-blind study of pramipexole with placebo and bromocriptine in
advanced Parkinson's disease. Mov Disord 2003; 18(10):1149-1156.
(185) Pogarell O, Gasser T, van Hilten JJ, Spieker S, Pollentier S, Meier D et al. Pramipexole in
patients with Parkinson's disease and marked drug resistant tremor: a randomised, double
blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry 2002; 72(6):713-
720.
(186) Wong KS, Lu CS, Shan DE, Yang CC, Tsoi TH, Mok V. Efficacy, safety, and tolerability of
pramipexole in untreated and levodopa-treated patients with Parkinson's disease. J Neurol
Sci 2003; 216(1):81-87.
(187) Barone P, Lamb J, Ellis A, Clarke Z. Sumanirole versus placebo or ropinirole for the
adjunctive treatment of patients with advanced Parkinson's disease. Mov Disord 2007;
22(4):483-489.
(188) LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson disease treated with rotigotine
transdermal system: PREFER Study. Neurology 2007; 68(16):1262-1267.
(189) Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP et al. Ropinirole 24-hour
prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology
2007; 68(14):1108-1115.
(190) Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E et al. Efficacy of
pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind,
double-dummy, randomised controlled trial. Lancet Neurol 2007; 6(6):513-520.
(191) Moller JC, Oertel WH, Koster J, Pezzoli G, Provinciali L. Long-term efficacy and safety of
pramipexole in advanced Parkinson's disease: results from a European multicenter trial.
Mov Disord 2005; 20(5):602-610.
(192) Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update:
pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord
2005; 20(5):523-539.
(193) A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with
Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005; 62(2):241-
248.
(194) Brodersen P, Philbert A, Gulliksen G, Stigard A. The effect of L-Deprenyl on on-off
phenomena in Parkinson's disease. Acta Neurol Scand 1985; 71(6):494-497.
(195) Golbe LI, Duvoisin RC. Double-blind trial of R-(-)-deprenyl for the "on-off" effect complicating
Parkinson's disease. J Neural Transm Suppl 1987; 25:123-129.
(196) Golbe LI, Lieberman AN, Muenter MD, Ahlskog JE, Gopinathan G, Neophytides AN et al.
Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin
Neuropharmacol 1988; 11(1):45-55.
(197) Hubble JP, Koller WC, Waters C. Effects of selegiline dosing on motor fluctuations in
Parkinson's disease. Clin Neuropharmacol 1993; 16(1):83-87.
(198) Lieberman AN, Gopinathan G, Neophytides A, Foo SH. Deprenyl versus placebo in
Parkinson disease: a double-blind study. N Y State J Med 1987; 87(12):646-649.
(199) Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F et al. Rasagiline as an
adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO,
Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised,
double-blind, parallel-group trial. Lancet 2005; 365(9463):947-954.
(200) Sivertsen B, Dupont E, Mikkelsen B, Mogensen P, Rasmussen C, Boesen F et al. Selegiline
and levodopa in early or moderately advanced Parkinson's disease: a double-blind
controlled short- and long-term study. Acta Neurol Scand Suppl 1989; 126:147-152.
(201) Waters CH, Sethi KD, Hauser RA, Molho E, Bertoni JM. Zydis selegiline reduces off time in
Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebocontrolled
study. Mov Disord 2004; 19(4):426-432.
233